FOSSIL is indicated for the treatment and prevention of Osteoporosis in Postmenopausal Women the treatment to increase Bone Mass in Men With Osteoporosis the treatment of Glucocorticoid-Induced Osteoporosis the treatment of Paget’s Disease of Bone
The action of FOSSIL on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. FOSSIL also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid disphosphatelipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farensylation and geranylgeranylation of small GTPase signaling proteins.
Oral bioavailability of the 10mg tablet in men(0.59%) was similar to that in women(0.78%) when administered after an overnight fast and 2 hours before breakfast. Volume of distribution- 28L Protein binding- 78% Half-life - >10 years
The recommended dosage is: One 70mg tablet once weekly. One 10mg tablet once daily.
Available in 70mg tablet Each strip contains 10 tablets